| Item type: | Article | ||||
|---|---|---|---|---|---|
| Journal or Publication Title: | Journal of Hepatology | ||||
| Publisher: | Elsevier | ||||
| Place of Publication: | AMSTERDAM | ||||
| Volume: | 76 | ||||
| Number of Issue or Book Chapter: | 1 | ||||
| Page Range: | pp. 123-134 | ||||
| Date: | 2022 | ||||
| Institutions: | Medicine > Lehrstuhl für Pathologie | ||||
| Identification Number: |
| ||||
| Keywords: | BETA-CATENIN; HIPPO PATHWAY; EFFECTORS YAP; LIVER-CANCER; TUMORIGENESIS; COMPLEX; HEPATOBLASTOMA; SUPPRESSES; ACTIVATION; EXPRESSION; YAP; TAZ; c-MYC; Hepatocellular carcinoma | ||||
| Dewey Decimal Classification: | 600 Technology > 610 Medical sciences Medicine | ||||
| Status: | Published | ||||
| Refereed: | Yes, this version has been refereed | ||||
| Created at the University of Regensburg: | Yes | ||||
| Item ID: | 56890 |
Web of ScienceAbstract
Background & Aims: Mounting evidence implicates the Hippo downstream effectors Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) in hepatocellular carcinoma (HCC). We investigated the functional contribution of YAP and/or TAZ to c-MYC-induced liver tumor development. Methods: The requirement for YAP and/or TAZ in c-Myc-driven hepatocarcinogenesis was ...
Abstract
Background & Aims: Mounting evidence implicates the Hippo downstream effectors Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) in hepatocellular carcinoma (HCC). We investigated the functional contribution of YAP and/or TAZ to c-MYC-induced liver tumor development. Methods: The requirement for YAP and/or TAZ in c-Myc-driven hepatocarcinogenesis was analyzed using conditional Yap, Taz, and Yap;Taz knockout (KO) mice. An hepatocyte-specific inducible TTR-CreERT2 KO system was applied to evaluate the role of YAP and TAZ during tumor progression. Expression patterns of YAP, TAZ, cMYC, and BCL2L12 were analyzed in human HCC samples. Results: We found that the Hippo cascade is inactivated in cMyc-induced mouse HCC. Intriguingly, TAZ mRNA levels and activation status correlated with c-MYC activity in human and mouse HCC, but YAP mRNA levels did not. We demonstrated that TAZ is a direct transcriptional target of c-MYC. In c-Myc induced murine HCCs, ablation of Taz, but not Yap, completely prevented tumor development. Mechanistically, TAZ was required to avoid c-Myc-induced hepatocyte apoptosis during tumor initiation. The anti-apoptotic BCL2L12 gene was identified as a novel target regulated specifically by YAP/TAZ, whose silencing strongly suppressed c-Myc-driven murine hepatocarcinogenesis. In cMyc murine HCC lesions, conditional knockout of Taz, but not Yap, led to tumor regression, supporting the requirement of TAZ for c-Myc-driven HCC progression. Conclusions: TAZ is a pivotal player at the crossroad between the c-MYC and Hippo pathways in HCC. Targeting TAZ might be beneficial for the treatment of patients with HCC and cMYC activation. Lay summary: The identification of novel treatment targets and approaches for patients with hepatocellular carcinoma is crucial to improve survival outcomes. We identified TAZ as a transcriptional target of c-MYC which plays a critical role in c-MYC-dependent hepatocarcinogenesis. TAZ could potentially be targeted for the treatment of patients with c-MYC-driven hepatocellular carcinoma. (C) 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Metadata last modified: 29 Feb 2024 12:41
Altmetric